ABSTRACT
Resumen Introducción: Son escasas las publicaciones sobre aplicación de escalas pronósticas para predecir el uso de ventilación mecánica invasiva (VMI) en neumonía por SARS-CoV-2. El objetivo del estudio fue evaluar el desempeño de las escalas PSI/PORT y SOFA para predecir el uso de VMI en pacientes con neumonía por SARS-CoV-2. Material y métodos: Estudio retrospectivo que incluyó pacientes hospitalizados con neumonía por SARS-CoV-2 del 01 de abril al 31 de mayo de 2020. Se realizó análisis de curvas ROC, calculando el área bajo la curva de las escalas PSI/PORT y SOFA, así como sensibilidad, especificidad y valores predictivos. Resultados: Se incluyó a 151 pacientes, con edad de 52 años (IQR 45-64); 69.5% eran hombres. Del total, 102 pacientes necesitaron VMI (67.5%). Las áreas bajo las curvas ROC para predecir VMI fueron: SOFA 0.71 (IC 95% 0.64-0.78) y PSI/PORT 0.78 (IC 95% 0.71-0.85). Al compararlas, no hubo significancia estadística (p = 0.08). Conclusiones: Las escalas SOFA y PSI/PORT pueden infraestimar la necesidad de VMI en la neumonía por SARS-CoV-2. En nuestro estudio, SOFA y PSI/PORT no tuvieron un buen desempeño para predecir el uso de VMI en pacientes hospitalizados con neumonía por SARS-CoV-2.
Abstract Introduction: There are few publications on the application of prognostic scales to predict the use of invasive mechanical ventilation (IMV) in SARS-CoV-2 pneumonia. Therefore, the study's objective was to evaluate the performance of PSI/PORT and SOFA in predicting the use of IMV in patients with SARS-CoV-2 pneumonia. Material and methods: A retrospective study that included hospitalized patients with SARS-CoV-2 pneumonia from April 01, 2020, to May 31, 2020. Analysis of ROC curves was performed, calculating the area under the curve for PSI/PORT and SOFA scores, as well as sensitivity, specificity, and predictive values. Results: 151 patients were included, aged 52 years (IQR 45-64); 69.5% were men. Of the total, 102 patients required IMV (67.5%). Area under the curve to predict IMV were: SOFA 0.71 (95% CI 0.64-0.78) and PSI/PORT 0.78 (95% CI 0.71-0.85). When comparing them, there was no statistical significance (p = 0.08). Conclusions: In patients with SARS-CoV-2 infection, SOFA and PSI/PORT may underestimate the need for IMV. In our study, SOFA and PSI/PORT score performed fair in predicting IMV use in hospitalized patients with SARS-CoV-2 pneumonia.
Resumo Introdução: Existem poucas publicações sobre a aplicação de escalas prognósticas para prever o uso de ventilação mecânica invasiva (VMI) na pneumonia por SARS-CoV-2. O objetivo do estudo foi avaliar o desempenho do PSI/PORT e SOFA para prever o uso de IMV em pacientes com pneumonia por SARS-CoV-2. Material e métodos: Estudo retrospectivo que incluiu pacientes internados com pneumonia por SARS-CoV-2 entre 1o de abril de 2020 e 31 de maio de 2020. Foi realizada análise da curva ROC, calculando a área sob a curva PSI/PORT e SOFA, bem como a sensibilidade, especificidade e valores preditivos. Resultados: Foram incluídos 151 pacientes, com idade de 52 anos (IQR 45-64); 69.5% eram homens. Do total, 102 pacientes necessitaram de VMI (67.5%). As áreas sob as curvas ROC para predizer VMI foram: SOFA 0.71 (IC 95% 0.64-0.78) e PSI/PORT 0.78 (IC 95% 0.71-0.85). Ao compará-los, não houve significância estatística (p = 0.08). Conclusões: SOFA e PSI/PORT podem subestimar a necessidade de VMI na pneumonia por SARS-CoV-2. Em nosso estudo, SOFA e PSI/PORT não tiveram bom desempenho na previsão do uso de VMI em pacientes hospitalizados com pneumonia por SARS-CoV-2.
ABSTRACT
BACKGROUND: Autoimmune hemolytic anemia (AIHA) is characterized by an autoimmune-mediated destruction of red blood cells. Warm AIHA (wAIHA) represents 60% of AIHA cases and is associated with the positive detection of IgG and C3d in the direct antiglobulin test (DAT). This study aimed to assess the clinical and laboratorial differences between primary and secondary wAIHA patients from a referral center in Mexico City. METHODS: All patients diagnosed with wAIHA in our institution from January 1992 to December 2015 were included and received corticosteroids as the first-line treatment. We analyzed the response to the first-line treatment, relapse-free survival, and time to splenectomy. RESULTS: Eighty-nine patients were included. Secondary wAIHA represented 55.1% of the cases. At diagnosis, secondary wAIHA patients showed a DAT mixed pattern more frequently than primary wAIHA patients (36.7 vs. 17.5%, P<0.001). In the survival analysis, patients with secondary wAIHA had a lower time to response (18 vs. 37 days, P=0.05), median disease-free survival (28.51 vs. 50.95 weeks, P=0.018), and time to splenectomy (43.5 vs. 61 wks, P=0.029) than those with primary wAIHA. Due to economic constraints, rituximab was considered as the third-line treatment in only two patients. CONCLUSION: Secondary wAIHA may benefit from a longer low-dose steroid maintenance period mainly due to its shorter time to relapse and time to splenectomy than primary wAIHA.